retifanlimab   Click here for help

GtoPdb Ligand ID: 11583

Synonyms: hPD-1 mAb 7(1.2) [3] | INCMGA0012 | MGA012
Compound class: Antibody
Comment: Retifanlimab (MGA012) is a clinical stage humanized IgG4 anti-PD-1 monoclonal antibody. It was developed by MacroGenics for anti-cancer potential. Retifanlimab blocks the interation between PD-1 and its ligands PD-L1/2, and it acts as an immune checkpoint inhibitor.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Retifanlimab is under evaluations in trials as a monotherapy (microsatellite instability-high endometrial cancer, Merkel cell carcinoma, squamous cell carcinoma of the anal canal (SCAC)) [2], and in combination with platinum-based chemotherapy (non-small cell lung cancer and SCAC). Retifanlimab holds FDA orphan drug designations for the treatment of anal cancer (March 2020) and Merkel cell carcinoma (October 2020). The EMA also granted orphan drug designation for anal cancer (October 2020).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04082364 Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3 Interventional MacroGenics MAHOGANY trial. 1